← Back to Search

Interactive Health Communication Application

MyCancerGene App for Cancer Genetic Testing Outcomes (MyCancerGene Trial)

N/A
Waitlist Available
Led By Angela R Bradbury, MD
Research Sponsored by Abramson Cancer Center of the University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
18 years of age or older
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline - 18 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will test whether a patient-centered genetic app can increase understanding of, and affective and behavioral responses to, genetic testing. The study hypothesis is that the intervention will be associated with increases in knowledge, decreases in distress, increases in communication with relatives and health care providers, and increases in performance of risk reducing health behaviors.

Who is the study for?
This trial is for men and women over 18 who have had genetic counseling and testing for hereditary cancer syndromes within the last 60 days. Participants must speak English and have access to the internet or a mobile device.
What is being tested?
The trial is testing 'MyCancerGene,' an interactive health application designed to improve patient understanding of genetic testing results, reduce distress, encourage communication with family and healthcare providers, and promote risk-reducing behaviors.
What are the potential side effects?
Since 'MyCancerGene' is an informational tool rather than a medication, it does not have physical side effects. However, learning about genetic risks can sometimes cause emotional or psychological distress.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline - 18 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline - 18 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Patient Reported Outcomes Measurement Information System (PROMIS)
The KnowGene Scale
Secondary study objectives
Behavioral Risk Factor Surveillance System Questionnaire (BRFSS)
Health and Diet Survey Dietary Guidelines Supplement
Impact of Events Scale (IES)
+4 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Intervention GroupExperimental Treatment1 Intervention
Individuals randomized to this arm will receive immediate access to the Interactive Health Communication Application.
Group II: Usual Care GroupActive Control1 Intervention
Individuals randomized to this arm will receive the standard clinical practice.

Find a Location

Who is running the clinical trial?

Abramson Cancer Center of the University of PennsylvaniaLead Sponsor
359 Previous Clinical Trials
108,036 Total Patients Enrolled
Abramson Cancer Center at Penn MedicineLead Sponsor
411 Previous Clinical Trials
158,537 Total Patients Enrolled
American Cancer Society, Inc.OTHER
227 Previous Clinical Trials
110,372 Total Patients Enrolled

Media Library

MyCancerGene (Interactive Health Communication Application) Clinical Trial Eligibility Overview. Trial Name: NCT04774445 — N/A
Cancer Research Study Groups: Intervention Group, Usual Care Group
Cancer Clinical Trial 2023: MyCancerGene Highlights & Side Effects. Trial Name: NCT04774445 — N/A
MyCancerGene (Interactive Health Communication Application) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04774445 — N/A
~19 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top